复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎肝纤维化患者的效果

doi:10.3760/cma.j.issn.1007-1245.2024.11.027

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (11): 1893-1898.DOI: 10.3760/cma.j.issn.1007-1245.2024.11.027

复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎肝纤维化患者的效果

宋云香¹ 侯明杰²

¹郑州大学附属传染病医院河南省传染病医院郑州市第六人民医院药学部，郑州450015；²郑州大学附属传染病医院河南省传染病医院郑州市第六人民医院感染科，郑州　450015

收稿日期:2023-03-09 出版日期:2024-06-01 发布日期:2024-06-25
通讯作者: 宋云香，Email：lyzxyyhn@sina.com
基金资助:
“十三五”艾滋病和病毒性肝炎等重大传染病防治科技重大专项（2017ZX10202101-003-004）

Clinical efficacy of Fufang Biejia Ruangan tablets combined with entecavir for patients with chronic hepatitis B and hepatic fibrosis

Song Yunxiang¹, Hou Mingjie²

¹Department of Pharmacy, Hospital of Infectious Diseases Affiliated to Zhengzhou University, Henan Provincial Hospital of Infectious Diseases, Zhengzhou Sixth People's Hospital, Zhengzhou 450015, China; ²Department of Infectious Diseases, Hospital of Infectious Diseases Affiliated to Zhengzhou University, Henan Provincial Hospital of Infectious Diseases, Zhengzhou Sixth People's Hospital, Zhengzhou 450015, China

Received:2023-03-09 Online:2024-06-01 Published:2024-06-25
Contact: Song Yunxiang, Email: lyzxyyhn@sina.com
Supported by:
Key Special Scientific and Technological Project of Thirteenth Five-years Plan for Prevention and Treatment of Major Infectious Diseases, Such as HIV, Viral Hepatitis, etc. (2017ZX10202101-003-004)

摘要/Abstract

摘要：

目的　探讨复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎（chronic hepatitis B，CHB）肝纤维化患者的效果。方法　选取2020年8月至2021年8月郑州市第六人民医院收治的80例CHB肝纤维化患者进行随机对照试验。采用随机数字表法将其分为观察组和对照组，每组40例。观察组脱落3例［7.5%（3/40）］，对照组脱落2例［5.00%（2/40）］。观察组37例，男27例，女10例，年龄（40.34±9.62）岁，乙型肝炎E抗原（hepatitis B E antigen，HBeAg）阳性率23（62.20%），丙氨酸氨基转移酶（alanine transaminase，ALT）（198.52±50.73）U/L；纤维化分期F1～F4分别有6例、16例、10例、5例。对照组38例，男29例，女9例，年龄（39.58±10.17）岁，HBeAg阳性率22（57.90%），ALT（193.66±47.79）U/L，纤维化分期F1～F4分别有7例、14例、12例、5例。对照组口服恩替卡韦片，0.5 mg/次，1次/d治疗；观察组则在此基础上口服复方鳖甲软肝片治疗，2.0 g/次，3次/d；两组均治疗12个月。比较两组治疗前和治疗6、12个月时ALT复常率和乙型肝炎病毒脱氧核糖核酸（hepatitis B virus deoxyribonucleic acid，HBV DNA）转阴率；治疗前及治疗6、12个月时采用化学发光法测定两组患者血清肝纤维化标志物［透明质酸（hyaluronic acid，HA）、Ⅲ型前胶原（procollagen type Ⅲ protein，PCⅢ）、层黏连蛋白（laminin，LN）、Ⅳ型胶原（Ⅳ collagen，CⅣ）］水平，并运用肝脏瞬时弹性探测仪测量其肝硬度测定值（liver stiffness measurements，LSM）；同时统计两组不良反应发生情况。采用χ²检验、t检验和方差分析。结果　治疗6、12个月时，观察组和对照组ALT复常率均高于治疗前（χ²=75.542、71.356，均P<0.05）；治疗6、12个月时，两组ALT复常率对比，差异均无统计学意义（均P>0.05）。治疗6、12个月时，观察组和对照组HBV DNA转阴率均高于治疗前（χ²=71.101、73.020，均P<0.05）。治疗6、12个月时，观察组HA［（103.90±33.78）μg/L比（121.53±37.04）μg/L、（86.68±26.72）μg/L比（100.61±28.73）μg/L］、PCⅢ［（116.73±29.54）μg/L比（132.73±32.79）μg/L、（89.21±25.30）μg/L比（104.51±28.27）μg/L］、LN［（110.72±30.97）μg/L比（126.84±33.89）μg/L、（92.50±28.40）μg/L比（107.42±30.21）μg/L］、CⅣ［（92.50±32.61）μg/L比（109.15±35.34）μg/L、（73.38±23.05）μg/L比（86.77±26.85）μg/L］均低于对照组（均P<0.05）；治疗6、12个月时，观察组LSM均低于对照组［（7.27±2.15）kPa比（9.84±2.52）kPa、（6.50±1.94）kPa比（7.61±2.26）kPa，均P<0.05］。所有患者均未见严重不良反应。结论　复方鳖甲软肝片联合恩替卡韦在逆转CHB患者肝纤维化上具有明显的协同效应，且长期治疗有利于持续稳定地改善患者肝纤维化，且安全性好。

关键词:

慢性乙型肝炎肝纤维化, 恩替卡韦, 复方鳖甲软肝片, 肝纤维化标志物, 肝硬度测定值

Abstract:

Objective　To investigate the effect of Fufang Biejia Ruangan tablets combined with entecavir for patients with chronic hepatitis B (CHB) and hepatic fibrosis. Methods　A total of 80 patients with CHB and liver fibrosis treated at Zhengzhou Sixth People's Hospital from August 2020 to August 2021 were selected for the randomized controlled trial, and were divided into an observation group and a control group by the random number table method, with 40 cases in each group. Three cases dropped out in the observation group [7.5% (3/40)], and 2 cases in the control group [5.00% (2/40)]. There were 37 cases in the observation group, including 27 males and 10 females; they were (40.34±9.62) years old; the hepatitis B E antigen (HBeAg) positive rate was 62.20% (23/37); the alanine transaminase (ALT) level was (198.52±50.73) U/L; there were 6, 16, 10, and 5 cases of F1-F4 of fibrosis stage, respectively. There were 38 cases in the control group, including 29 males and 9 females; they were (39.58±10.17) years old; the HBeAg positive rate was 22 (57.90%); the ALT level was (193.66±47.79) U/L; there were 7, 14, 12, and 5 cases of F1-F4 of fibrosis stages, respectively. The control group orally took entecavir tablets, 0.5 mg/time, once per day, and the observation group orally took entecavir tablets, 0.5 mg/time, once per day, and Fufang Biejia Ruangan tablets, 2.0 g/time, 3 times/d, for 12 months. The normalcy rates of ALT and negative conversion rates of hepatitis B virus deoxyribonucleic acid (HBV DNA) were compared between the two groups before the treatment and after 6 and 12 months' treatment. The serum markers of liver fibrosis [hyaluronic acid (HA), procollagen type Ⅲ protein (PCⅢ), laminin (LN), and type Ⅳ collagen (CⅣ)] in both groups were determined by chemiluminescence before the treatment and after 6 and 12 months' treatment. The liver stiffness measurernents (LSM) were measured by a transient elastic tester. At the same time, the incidences of adverse reactions in the two groups were analyzed. χ² and t tests and analysis of variance were applied. Results　After 6 and 12 months' treatment, the ALT normalcy rates in both the observation group and the control group were higher than those before the treatment (χ²=75.542 and 71.356; both P<0.05). There were no statistical differences in the ALT normalcy rates after 6 and 12 months' treatment between the two groups (both P>0.05). After 6 and 12 months' treatment, the negative HBV DNA conversion rates in the observation group and the control group were higher than those before the treatment (χ²=71.101 and 73.020; both P<0.05). After 6 and 12 months' treatment, the levels of HA [(103.90±33.78) μg/L vs. (121.53±37.04) μg/L and (86.68±26.72) μg/L vs. (100.61±28.73) μg/L], PCⅢ [(116.73±29.54) μg/L vs. (132.73±32.79) μg/L and (89.21±25.30) μg/L vs. (104.51±28.27) μg/L], LN [(110.72±30.97) μg/L vs. (126.84±33.80) μg/L and (92.50±28.40) μg/L vs. (107.42±30.21) μg/L], and CⅣ [(92.50±32.61) μg/L vs. (109.15±35.34) μg/L and (73.38±23.05) μg/L vs. (86.77±26.85) μg/L] in the observation group were lower than those in the control group (all P<0.05). After 6 and 12 months' treatment, the LSM's in the observation group were significantly lower than those in the control group [(7.27±2.15) kPa vs. (9.84±2.52) kPa and (6.50±1.94) kPa vs. (7.61±2.26) kPa; both P<0.05]. No serious adverse events were observed in all the patients. Conclusion　Fufang Biejia Ruangan tablets combined with entecavir has obvious synergistic effect on reversing liver fibrosis in patients with CHB, and the long-term treatment is beneficial to continuously and stably improve the patients' liver fibrosis and is safe.

Key words:

Hepatic fibrosis caused by chronic hepatitis B, Entecavir, Fufang Biejia Ruangan tablets, Hepatic fibrosis markers, Liver stiffness measurement value

宋云香侯明杰.

复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎肝纤维化患者的效果 [J]. 国际医药卫生导报, 2024, 30(11): 1893-1898.

Song Yunxiang, Hou Mingjie.

Clinical efficacy of Fufang Biejia Ruangan tablets combined with entecavir for patients with chronic hepatitis B and hepatic fibrosis [J]. International Medicine and Health Guidance News, 2024, 30(11): 1893-1898.

参考文献

[1] Liu J, Zhang S, Wang Q, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study [J]. Lancet Infect Dis, 2016, 16(1): 80-86. DOI: 10.1016/S1473-3099(15)00218-2.
[2] 李曹杰,李嘉浚,陈荣新.肝纤维化与肝癌免疫微环境的研究进展[J].复旦学报(医学版),2023,50(6):889-896. DOI: 10.3969/j.issn.1672-8467.2023.06.013.
[3] 南然,席奇,刘永刚等.恩替卡韦联合复方鳖甲软肝片治疗乙型肝炎肝衰竭的临床效果[J].检验医学与临床,2023,20(21):3105-3108, 3113. DOI: 10.3969/j.issn.1672-9455. 2023.21.001.
[4] 燕飞,陈欣菊,赵晴等.复方鳖甲软肝片联合苯扎贝特治疗胆汁性肝硬化的临床研究[J].现代药物与临床,2021,36(10):2073-2077. DOI: 10.7501/j.issn.1674-5515.2021. 10.015.
[5] 王贵强,王福生,成军,等.慢性乙型肝炎防治指南(2015更新版)[J].胃肠病学, 2016, 21(4): 219-240. DOI: 10.3969/j.issn.1008-7125.2016.04.007.
[6] 肝纤维化中西医结合诊疗指南[J].中国肝脏病杂志(电子版),2010,2(4):54-59. DOI: 10.3969/j.issn.1674-7380. 2010.04.015.
[7] 蔡敏, 刘娜, 潘玉, 等.安络化纤丸联合恩替卡韦治疗慢性乙型肝炎肝纤维化的Meta分析[J]. 现代中西医结合杂志, 2017, 26(30): 3341-3345. DOI: 10.3969/j.issn.1008- 8849. 2017.30.011.
[8] Wang L, Wang B, You H, et al. Platelets' increase is associated with improvement of liver fibrosis in entecavir-treated chronic hepatitis B patients with significant liver fibrosis [J]. Hepatol Int, 2018, 12(3): 237-243. DOI: 10.1007/s12072-018-9864-z.
[9] 唐礼瑞, 郭涛, 陶艳艳, 等.扶正化瘀胶囊联合核苷(酸)类药物治疗慢性乙型肝炎肝纤维化的初步系统评价[J]. 中西医结合肝病杂志, 2013, 23(3): 183-187. DOI: 10.3969/j.issn.1005-0264.2013.03.024.
[10] 曹正民,李彦波,武庆娟,等.从"阳化气, 阴成形"理论探讨肝纤维化的中医辨治[J].中西医结合肝病杂志,2023,33(12):1130-1131. DOI: 10.3969/j.issn.1005-0264.2023. 010.018.
[11] 李晓斌,胡世平."养阴以化瘀"在肝纤维化治疗中的应用探讨[J].现代中医临床, 2023, 30(6): 32-35. DOI:10.3969/j.issn.2095-6606.2023.06.007.
[12] 姚春苗,杨玲,尚雪妍等.三仁汤合茵陈五苓散加减联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝病(湿热蕴结证)的疗效及对肝纤维化和血清IL-1β、内脂素、HO-1水平的影响[J].中国肝脏病杂志(电子版),2023,15(3):56-63. DOI: 10.3969/j.issn.1674-7380.2023.03.009.
[13] 杨宇, 赵月涵, 庄海, 等.复方鳖甲软肝片防治大鼠肝纤维化作用及机制[J]. 贵州医科大学学报, 2018, 43(12): 1380-1385. DOI:10.19367/j.cnki.1000-2707. 2018.12.004
[14] 段雪琳, 黎桂玉, 李树民, 等.复方鳖甲软肝片联合恩替卡韦对慢性乙型肝炎血清肝纤维化标志物影响的Meta分析[J]. 中国医院药学杂志,2015, 35(19): 1762-1765. DOI: 10.13286/j.cnki.chinhosppharmacyj.2015.19.13.
[15] 邬振国, 周高东, 陈永永, 等. 复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床研究[J]. 药物评价研究, 2017, 40(3): 351-355. DOI: 10.7501/j.issn. 1674-6376.2017.03.012.
[16] Liu J, Ji Y, Ai H, Ning B, et al. Liver shear-wave velocity and serum fibrosis markers to diagnose hepatic fibrosis in patients with chronic viral hepatitis B [J]. Korean J Radiol, 2016, 17(3): 396-404. DOI: 10.3348/kjr.2016.17.3.396.
[17] 张孝盈,钱静,李萍,等.无创方法诊断慢性乙型肝炎病毒携带者肝纤维化的临床价值[J]. 中华肝脏病杂志, 2018, 26(5): 332-336. DOI: 10.3760/cma.j.issn.1007-3418. 2018.05.004.
[18] 杨年欢, 袁国盛, 周宇辰, 等.恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化96周的临床疗效[J]. 南方医科大学学报, 2016, 36(6): 775-779. DOI: 10.3969/j.issn.1673-4254.2016.06.07.
[19] 相维婷,余松,曾瑞琦. 复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎肝硬化代偿期临床研究[J]. 新中医,2024,56(1):83-87. DOI: 10.13457/j.cnki.jncm.2024.01.016.
[20] 田昊,宫雪莲,丁坤. 恩替卡韦联合复方鳖甲软肝片治疗HBeAg阳性失代偿期肝硬化患者的疗效分析[J]. 国际医药卫生导报,2023,29(10):1404-1408. DOI: 10.3760/cma.j.issn.1007-1245.2023.10.016.
[21] 邱玲玲,陈雯,支星,等. 复方鳖甲软肝片治疗肝纤维化的机制研究[J]. 国际医药卫生导报, 2021, 27(9):1267-1273. DOI: 10.3760/cma.j.issn.1007-1245.2021.09.001.
[22] 李红兵,董黛青,卜贤玉,等. 复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎伴脾肿大患者疗效观察[J]. 中国现代医学杂志,2017,27(2):106-109. DOI: 10.3969/j.issn. 1005-8982.2017.02.020.
[23] 汤振和. 复方鳖甲软肝片在乙型肝炎肝硬化患者中的应用效果观察[J]. 实用中西医结合临床, 2022, 22(16): 96-99. DOI:10.13638/j.issn.1671-4040.2022.16.028.
[24] 朱海洋,高红伟,韩仙芝,等. 恩替卡韦联合复方鳖甲软肝片治疗不同时期慢性乙型肝炎肝硬化疗效及其与趋化因子受体的关系[J]. 中西医结合肝病杂志,2021,31(5):405-408. DOI: 10.3969/j.issn.1005-0264.2021.05.006.
[25] 邱实,程静屏. 扶正化瘀片联合复方鳖甲软肝片对肝硬化患者肝纤维化及炎症指标的改善作用[J]. 中国医药,2021,16(12):1833-1836. DOI: 10.3760/j.issn.1673-4777. 2021.12.017.

复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎肝纤维化患者的效果

Clinical efficacy of Fufang Biejia Ruangan tablets combined with entecavir for patients with chronic hepatitis B and hepatic fibrosis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics